IDX719: Additional Phase IIa data
Idenix reported additional data from 64 treatment-naïve patients with HCV genotypes 1, 2, 3 or 4 infection evaluating IDX719 for 3 days in the placebo-controlled Phase IIa portion of a double-blind, U.S. Phase I/IIa trial. In 29 patients with HCV genotype 1a infection, mean maximum viral load reductions from baseline ranged from 3.2-3.6 log10 IU/mL across all doses of IDX719. In 5 patients with HCV genotype 1b infection, mean maximum viral load reductions from baseline were 3 log10 IU/mL for once-daily 25 mg IDX719 and 4.3 log10 IU/mL for once-daily 50 mg IDX719.
No patients experienced viral rebound defined as a >1 log10 IU/mL increase over the lowest viral load during the treatment period and maximum viral load reductions were typically achieved with 24-72 hours post-dose. Patients with HCV genotype 1 infection received placebo, 25, 50 or 100 mg once-daily IDX719 or 50 mg twice-daily IDX719 for 3 days. Patients with HCV genotypes 2, 3 or 4 infection received placebo, 100 mg once-daily IDX719 or 50 mg twice-daily IDX719 for 3 days. Data were presented at the American Association for the Study of Liver Diseases meeting in Boston. ...